References
- American Medical Association. (2016, November 2). 8 reasons patients don’t take their medications. Retrieved from https://wire.ama-assn.org/practice-management/8-reasons-patients-dont-take-their-medications
- Calabrese, S. K., & Underhill, K. (2015). How stigma surrounding the use of HIV preexposure prophylaxis undermines prevention and pleasure: A call to destigmatize “Truvada whores”. American Journal of Public Health, 105(10), 1960–1964. doi: 10.2105/AJPH.2015.302816
- Centers for Disease Control and Prevention. (2018, March 7). 2018 conference on retroviruses and opportunistic infections. Retrieved from https://www.cdc.gov/nchhstp/newsroom/2018/croi-2018.html
- Eaton, L. A., Matthews, D. D., Bukowski, L. A., Friedman, M. R., Chandler, C. J., Whitfield, D. L., … POWER Study Team. (2018). Elevated HIV prevalence and correlates of PrEP use among a community sample of black men who have sex with men. JAIDS Journal of Acquired Immune Deficiency Syndromes, 79(3), 339–346. doi: 10.1097/QAI.0000000000001822
- Golub, S. A., Gamarel, K. E., Rendina, H. J., Surace, A., & Lelutiu-Weinberger, C. L. (2013). From efficacy to effectiveness: Facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care and STDs, 27(4), 248–254. doi: 10.1089/apc.2012.0419
- Haire, B. G. (2015). Preexposure prophylaxis-related stigma: Strategies to improve uptake and adherence–a narrative review. HIV/AIDS (Auckland, NZ), 7, 241.
- HIV.gov. (2018, March 6). HIV prevention pill not reaching most Americans who could benefit – especially people of color. Retrieved from https://www.hiv.gov/blog/hiv-prevention-pill-not-reaching-most-americans-who-could-benefit-especially-people-color
- Horberg, M., & Raymond, B. (2013). Financial policy issues for HIV pre-exposure prophylaxis: cost and access to insurance. American Journal of Preventive Medicine, 44(1), S125–S128. doi: 10.1016/j.amepre.2012.09.039
- Koenig, H. C., Mounzer, K., Daughtridge, G. W., Sloan, C. E., Lalley-Chareczko, L., Moorthy, G. S., … Tebas, P. (2017). Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis. HIV Medicine, 18(6), 412–418. doi: 10.1111/hiv.12518
- Landovitz, R. J., Beymer, M., Kofron, R., Amico, K. R., Psaros, C., Bushman, L., … Jordan, W. C. (2017). Plasma tenofovir levels to support adherence to TDF/FTC preexposure prophylaxis for HIV prevention in MSM in Los Angeles, California. JAIDS Journal of Acquired Immune Deficiency Syndromes, 76(5), 501–511. doi: 10.1097/QAI.0000000000001538
- Lelutiu-Weinberger, C., & Golub, S. A. (2016). Enhancing PrEP access for black and Latino men who have sex with men. JAIDS Journal of Acquired Immune Deficiency Syndromes, 73(5), 547–555. doi: 10.1097/QAI.0000000000001140
- Riddell, J., Amico, K. R., & Mayer, K. H. (2018). HIV preexposure prophylaxis: a review. The Journal of the American Medical Association, 319(12), 1261–1268. doi: 10.1001/jama.2018.1917
- U.S. Preventative Services Task Force. (2018, November). Draft recommendation statement: prevention of human immunodeficiency virus (HIV) infection: Pre-exposure prophylaxis.
- Van der Elst, E. M., Mbogua, J., Operario, D., Mutua, G., Kuo, C., Mugo, P., … Sanders, E. J. (2013). High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: Qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS and Behavior, 17(6), 2162–2172. doi: 10.1007/s10461-012-0317-8
![Supercharge Your Next Research Paper: Research and write your next paper with Jenni AI.]({"type":"image" , "src" : "/sda/112442/MPU-social-sciences.png"})